Remove DNA Remove RNA Remove Therapies
article thumbnail

Junk DNA: How the dark genome is changing RNA therapies

Drug Discovery World

Samir Ounzain , PhD, CEO & Co-Founder of HAYA Therapeutics, looks at how a better understanding of our DNA can lead to increased activity for RNA therapeutics. The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines.

RNA 130
article thumbnail

Harnessing circRNAs could “change the landscape” of cancer therapy

Drug Discovery World

“Over the past decade, research into circRNAs has emerged as a vital area of study, revealing the crucial role these unique RNA molecules play in cancer biology,” said Professor Conn. “By We’ve also discovered that high levels of circRNAs in certain people can cause mutations in their DNA which results in leukaemia.”

Therapies 147
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Conversations from ESMO Targeted Anticancer Therapies Congress 2024 

Drug Discovery World

DDW’s Megan Thomas caught up with Oliver Rausch, Chief Scientific Officer at Storm Therapeutics, following the ESMO Targeted Anticancer Therapies Congress 2024, a global meeting focusing on promising new anticancer targets and agents, focusing on those in early phase clinical development.

Therapies 162
article thumbnail

RNA interference method could treat muscular dystrophy

Drug Discovery World

Japanese researchers propose using RNA interference for correcting a mistake in the genetic code of patients with Fukuyama muscular dystrophy. . Using RNA interference, researchers restored the normal biological function of FKTN in patient-derived cells, offering hope for a new therapy. . Modifying RNA function.

RNA 130
article thumbnail

Using gene therapy to live longer, healthier lives

Drug Discovery World

She discusses with DDW’s Megan Thomas the company’s lead programme; a gene therapy called ER-100. Life Biosciences’ gene therapy approach differs from traditional gene replacement and gene editing approaches in that the company are not altering the DNA sequence.

Therapies 147
article thumbnail

Plasmid DNA Design Considerations for Cell and Gene Therapy

Fierce BioTech

Plasmid DNA Design Considerations for Cell and Gene Therapy Cell and Gene therapy organizations must balance the need for rapid clinical progression and stringent quality expectations throughout development.

DNA 52
article thumbnail

Genetic biomarkers could personalise therapy for TNBC

Drug Discovery World

Additionally, patients whose cancer has spread but who have not yet received chemotherapy, and whose primary tumours have markers of faults in genes linked to DNA repair pathways, tend to respond better to carboplatin. “Our findings paint a complex picture – with many, dynamic factors driving how tumours respond to treatment.”

Therapies 130